SUBSCRIBE
SUBSCRIBE

Jennifer C. Smith-Parker

Director of Insights

Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.

Insights
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early testing, smart IP and regulatory planning, and scalable CMC choices can help founders reach first-in-human faster.
April 6, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
In this episode of Denatured, you’ll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech’s next big frontier.
April 2, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
3D rendering of a Syringe Shield and multiple instances of the international radioactive hazard symbol or the trefoil icon.
Insights
The Brave New World of Radiotherapeutics
Convergent Therapeutics’ Dr. Philip Kantoff and Plus Therapeutics’ Dr. Marc Hedrick discuss how unmet medical needs, maturing isotope supply chains and innovative delivery are positioning targeted radiation as oncology’s next big platform.
April 1, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
Beyond Buzzwords in Longevity Investing
In this episode of Denatured, you’ll listen to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We speak about how developers in the longevity space should stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly tackle age-related conditions.
March 26, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Hourglass lying on pink background - Concept of time and woman
Insights
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly target specific, age-related diseases, according to two investors in a discussion with BioSpace.
March 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
In this episode of Denatured, you’ll listen to Viswa Colluru, CEO and founder of Enveda and Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest. We speak about how AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases to garner investor interest.
March 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Symbolic image: Life as a hurdling - person faces challenges
Insights
AI Drug Discovery Platforms Face New Investor Bar
In a highly competitive space, AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases. Promises of faster, cheaper drug discovery are not enough to entice strong investor engagement.
March 17, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
From Two Trials to One, Sponsors Face a Higher Standard
In this episode of Denatured, you’ll listen to Oxana Iliach, senior director of regulatory strategy at Certara and Vera Pomerantseva, director of product management for risk-based quality management at eClinical Solutions. We speak about how the FDA’s latest decision to have one, rather than two pivotal studies, for new drug applications raises the bar for data collection and risk-based management.
March 12, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Flat 3d isometric business people came from different way but have same target. Business team and target concept.
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
Single-trial approvals are raising the bar on trial design and execution. The new paradigm is pushing sponsors to plan earlier, step up their data and risk‑based quality management and use modeling and AI to generate one compelling, regulator‑ready evidence package.
March 10, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
In this episode of Denatured, you’ll listen to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We’ll be speaking about how to combine nondilutive funding and family office money into a unified strategy that gets companies through the drug development valley of death.
March 5, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
cloud with rain of coins on blue background. minimal concept of investment, success and cryptocurrencies. 3d rendering
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter,” early stage biotechs are rewriting their financing strategies around nondilutive capital and targeted private wealth.
March 4, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
In this episode of Denatured, you’ll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therapeutics. We’ll be speaking about patient-pharma collaborations accelerating trials and hope, advances in ALS biology understanding and biomarker-driven endpoints.
February 26, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Insights
Historic ALS Investment Signals New Treatment Momentum
The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics’ first patient dosing in its TDP-43-targeting PIONEER-ALS trial and EverythingALS’ pharma consortia driving biomarker innovations and trial alignment.
February 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
February 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
In the incredibly hot obesity drug space, with more than 700 clinical trials ongoing, Verdiva Bio and MitoRx leaders discuss how next-generation therapies are targeting lean muscle preservation, extended efficacy and better safety profiles to enable lifelong weight management.
February 19, 2026
 · 
2 min read
 · 
Jennifer C. Smith-Parker
Load More